A Randomized, Double-blind, Active-controlled, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combined Administration of AD-2281 and AD-2282 in Patients with Primary Hypercholesterolemia
Latest Information Update: 02 Jan 2025
Price :
$35 *
At a glance
- Drugs AD 2281/AD 2282 (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Addpharma
- 02 Jan 2025 New trial record